- Biotechnology
- Thursday, 28 Nov 2019
Jubilant Biosys Commences Major Capacity Expansions for its Drug Discovery Services Business
Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Lifesciences Limited, today announced commencement of two expansion projects in Greater Noida and Bengaluru.
Due to growing customer demand for its range of functional and integrated drug discovery services, Jubilant Biosys has started design and construction of brand new and state-of-the-art chemistry services laboratories on the existing Jubilant Greater Noida site. The chemistry FTE capacity will be doubled and operations are expected to commence from H2 2020. The new site can accommodate up to 500 Chemistry FTE's. The site will be designed for the highest global compliance standards and deliver superior speed and quality in the entire drug discovery process.
Jubilant Biosys has obtained a 10-acre plot in the Devanahalli Industrial Park which is adjacent to the International Airport. A completely new drug discovery services site will be constructed in phases for further expansions.
In addition, we have formed a new digital business unit comprising of Bio-Informatics, Data-curation for AI/ML, TrialStat EDC software as well as discovery focussed AI/ML capabilities. This business unit will also further expand on the new site and deliver increased benefits to our customers.
Marcel Velterop, President – Jubilant Biosys and CDMO, said: "The improving customer confidence earned through exemplary scientific execution and a positive outlook in the global drug discovery industry has resulted in the largest investment program in Jubilant Biosys since its inception. We will soon be able to offer our customers much improved capacity and services as well as ability to deliver an integrated IND package along with superior functional discovery services. A combination of the best talent and state-of-the-art technology and instrumentation will be offered to pursue drug discovery collaborations and help deliver new innovation to patients faster than ever. "
Related Industry Updates
Increasing Incidence of Genetic Diseases will enhance the dPCR and qPCR Market
Aug 31, 2019
Philogen Received Combination Pack Approval for Nidlegy
Jun 24, 2020
Mycoplasma Testing Market 2021 Research Report Overview by Top Key Players, Opportunities, Key Drivers, Application and Regional Outlook To 2027
May 10, 2021
Linear Particle Accelerators Market by Demand Analysis, Manufacturers Share, Regions, Risk Analysis, Driving Forces, Deployment Model, Production Scope, Type and Application, Forecast to 2027
May 05, 2021
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
Apr 27, 2020
Innovent Announces the NMPA Granted Marketing Approval for BYVASDA® (Bevacizumab Biosimilar) in China
Jun 19, 2020
Enzychem Lifesciences Appoints Duke Medical Coronavirus Task Force Expert Dr. Cameron Wolfe to Lead Development of EC-18 as a COVID-19 Therapeutic Drug
May 19, 2020